Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025
Y-mAbs Therapeutics (NASDAQ: YMAB), a commercial-stage biopharmaceutical company specializing in radioimmunotherapy and antibody-based cancer treatments, has scheduled its Q1 2025 financial results announcement for Tuesday, May 13, 2025, before market open. The company will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results. Investors can access the webcast through Y-mAbs' Investor Relations website, where it will remain archived for at least 30 days.
Y-mAbs Therapeutics (NASDAQ: YMAB), un'azienda biofarmaceutica in fase commerciale specializzata in radioimmunoterapia e trattamenti oncologici a base di anticorpi, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per martedì 13 maggio 2025, prima dell'apertura dei mercati. La società terrà una conference call e una webcast alle 8:00 a.m. ET dello stesso giorno per discutere i risultati. Gli investitori potranno accedere alla webcast tramite il sito web delle Relazioni con gli Investitori di Y-mAbs, dove resterà disponibile in archivio per almeno 30 giorni.
Y-mAbs Therapeutics (NASDAQ: YMAB), una empresa biofarmacéutica en etapa comercial especializada en radioinmunoterapia y tratamientos contra el cáncer basados en anticuerpos, ha programado el anuncio de los resultados financieros del primer trimestre de 2025 para el martes 13 de mayo de 2025, antes de la apertura del mercado. La compañía realizará una llamada conferencia y una transmisión en vivo a las 8:00 a.m. ET del mismo día para discutir los resultados. Los inversionistas podrán acceder a la transmisión a través del sitio web de Relaciones con Inversionistas de Y-mAbs, donde permanecerá archivada durante al menos 30 días.
Y-mAbs Therapeutics (NASDAQ: YMAB)는 방사면역치료 및 항체 기반 암 치료를 전문으로 하는 상업 단계의 바이오제약 회사로, 2025년 1분기 재무 실적 발표를 2025년 5월 13일 화요일, 장 개장 전으로 예정했습니다. 회사는 같은 날 동부 표준시 오전 8시에 실적을 논의하기 위한 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 투자자들은 Y-mAbs 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 해당 웹캐스트는 최소 30일간 아카이브로 보관됩니다.
Y-mAbs Therapeutics (NASDAQ : YMAB), une société biopharmaceutique en phase commerciale spécialisée dans la radio-immunothérapie et les traitements anticancéreux à base d’anticorps, a prévu l'annonce des résultats financiers du premier trimestre 2025 pour le mardi 13 mai 2025, avant l'ouverture des marchés. La société organisera une conférence téléphonique et une webdiffusion à 8h00 ET le même jour pour discuter des résultats. Les investisseurs pourront accéder à la webdiffusion via le site des Relations Investisseurs de Y-mAbs, où elle restera archivée pendant au moins 30 jours.
Y-mAbs Therapeutics (NASDAQ: YMAB), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf Radioimmuntherapie und antibodybasierte Krebstherapien spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für Dienstag, den 13. Mai 2025, vor Markteröffnung geplant. Das Unternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse zu besprechen. Investoren können über die Investor-Relations-Website von Y-mAbs auf den Webcast zugreifen, wo er mindestens 30 Tage lang archiviert bleibt.
- None.
- None.
PRINCETON, N.J., May 06, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced it will report results for the first quarter 2025 before the market open on Tuesday, May 13, 2025.
Y-mAbs will hold a conference call and webcast to discuss these results on Tuesday, May 13, 2025 at 8:00 a.m. ET. A live audio webcast of the call will be available on the Investor Relations section of the Company’s website at https://ir.ymabs.com/events-and-presentations/events. The webcast will be archived for at least 30 days.
About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.
Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2025 and beyond. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company’s business is subject to risks and uncertainties affecting the Company including those described in the “Risk Factors” section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and the Company’s Quarterly Report on Form 10-Q for the quarterly periods ended March 31, 2024, and September 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
SADA®, SADA PRIT™, DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.
Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com
FAQ
When will Y-mAbs (YMAB) report its Q1 2025 earnings?
What time is Y-mAbs (YMAB) Q1 2025 earnings call?
Where can I access Y-mAbs (YMAB) Q1 2025 earnings webcast?
What is Y-mAbs Therapeutics' main business focus?
